diabetes glp-1 vs sglt2 Benefits of treatment with SGLT2i and GLP-1RA based on their direct and Type 2 Diabetes - Treatment

Studies showed a remarkable effect on people with obesity: The SELECT Trial found that MACE (major adverse CVD event) risk was reduced by 20% in adults with obesity without T2D in the group taking semaglutide

In a recent study, participants who took tirzepatide lost an average of 12.4% of their body weight over 72 weeks

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study

Labs are typically covered by insurance though there may be a co-pay

[DOI] [PMC free article] [PubMed] [Google Scholar] 9.Zheng Z., Zong Y., Ma Y., Tian Y., Pang Y., Zhang C., Gao J